Initiate coverage on Stryker with a Buy rating and a $340 price target. Temporary manufacturing bottlenecks and CEO transition uncertainty have discounted this premier MedTech compounder to 18.4 times earnings, offering 23% upside as operational backlogs clear and core volume growth persists.
Key points
- 18.4 times adjusted earnings is an overly punitive valuation for a medical technology leader delivering 9% organic volume growth.
- $16.60 a share in projected 2027 adjusted profit reflects 10.5% earnings expansion as production snarls clear and Mako shoulder launches scale.
- 23% upside to our $340 target offers an asymmetric entry into an enduring compounder after a 26% one-year pullback.
The call
Stryker trades at 18.4 times midpoint 2026 guidance and 16.7 times 2027 earnings. The market prices severe structural decay, treating transitory supply backorders at an Inari vascular facility and a planned leadership handover as permanent impairment of Stryker's procedural franchise. The current price requires long-term operating profit growth to slow abruptly below 5%.
Annual revenue trajectory and forecast ($ billions)- Reported revenue
- Forecast revenue
Source: Stryker SEC filings and desk forecasts. Values in billions of dollars.
We believe this pessimism is misplaced. Underlying surgical demand remains robust, with second-quarter organic shipments rising 9.0% on pure volume. As vascular manufacturing stabilizes and capital backlogs convert into installations, adjusted earnings will reach $16.60 in 2027. Re-rating to a conservative 20.5 times multiple drives the stock to $340.
Implied share price across FY27E forward P/E scenariosSource: Desk valuation model based on $16.60 FY27E adjusted EPS. Price of $276.97 marked.
Valuation
Our twelve-month target of $340 values Stryker at 20.5 times estimated 2027 adjusted profit. This multiple sits well below Stryker's historical 24 to 26 times median, building in a cushion for executive transition execution and tariff variability. The asymmetry heavily favors buyers, as even status-quo multiples yield positive returns.
| Metric | Estimate | Note |
|---|
| Current share price | $276.97 | Verified market close on October 8, 2026 |
| FY26E adjusted EPS | $15.03 | Midpoint of management guidance ($14.95 to $15.10) |
| FY27E adjusted EPS | $16.60 | 10.5% growth via operational leverage and backlog fulfillment |
| Target forward P/E | 20.5x | Modest recovery toward historical median of 24.0x |
| 12-month price target | $340.00 | Product of $16.60 EPS and 20.5x multiple |
| Implied return | +22.8% | Excludes 1.3% dividend yield ($3.52 annualized) |
Risks
- Supply bottlenecks in peripheral vascular persist into 2027, handing hospital accounts to competitors; watch quarterly Vascular organic sales for negative growth.
- Hospital capital expenditure freezes delay installation of high-margin Mako robotic suites; track quarterly MedSurg and Ortho Tech shipment conversion rates.
- Executive transition execution stumbles under incoming CEO Spencer Stiles; monitor operating margin expansion targets during early 2027 quarterly prints.
What would change my mind
We would cut our rating if organic sales growth falls below 6.5% alongside verified customer defections in peripheral vascular or joint replacement.